Back to top
more

Kiniksa Pharmaceuticals (KNSA)

(Delayed Data from NSDQ)

$25.44 USD

25.44
332,256

-0.28 (-1.09%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $25.44 0.00 (0.00%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Company News for Dec 29, 2021

Companies in The News Are: KNSA,AAPL,VIPS,CCL

Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 138% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Surge 100%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 100.2% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.16% and 21.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

New Strong Sell Stocks for January 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Company News for Oct 7, 2020

Companies in the news are: KNSA, GMDA, BNTX, NAKD

Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Company News for Jun 30, 2020

Companies in the news are: KNSA, TLSA, COTY, ICPT

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Spike in Coronavirus

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Nalak Das headshot

5 Stocks With Recent Price Strength on Upbeat Economic Data

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry

Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Kiniksa Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals

Nitish Marwah headshot

New Strong Buy Stocks for May 1st

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?

Is (KNSA) Outperforming Other Medical Stocks This Year?

Company News for Apr 1, 2020

Companies In The News Are: KNSA, EYEG, VBIV, EYES

Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.